Role of nanotechnology in therapeutics and diagnosis of Alzheimer’s disease
DOI:
https://doi.org/10.31117/neuroscirn.v7i1.225Keywords:
Alzheimer's disease, Nanomedicine, Nanotechnology, Diagnostics, NanoparticlesAbstract
Alzheimer's disease refers to a pathological topography accompanied by the loss of neurons in the brain regions including entorhinal cortex and hippocampus, resulting in memory impairment, cognitive dysfunction, behavioural problems, and difficulties in activities of daily living that ultimately lead to mortality. This disease typically affects the elderly population. Even if the underlying pathophysiological mechanisms are unclear, Alzheimer's disease is unquestionably associated with dysfunction in the cholinergic system, resulting in a decreased level of acetylcholine in specific brain regions, including the entorhinal cortex and hippocampus. Although significant progress has been made in understanding the molecular and cellular causes of Alzheimer's disease, there is presently no medication available to reduce or stop the loss of brain cells. As the number of individuals with Alzheimer's disease continues to rise, there is a pressing need to develop ways for early diagnosis and offer viable treatments to avert a public health crisis. In recent years, nanoparticles have been seriously studied as a diagnostic and therapeutic tool for Alzheimer's disease. Here, we discuss the recent growth in nanoparticles for Alzheimer's disease diagnosis and treatment.
References
Anton, N., Benoit, J.P. & Saulnier, P. (2008) Design and production of nanoparticles formulated from nano-emulsion templates-a review. Journal of Controlled Release. 128, 185–199. https://doi.org/10.1016/j.jconrel.2008.02.007
Aboofazeli, R. (2010). Nanometric-scaled emulsions (nanoemulsions). Iranian Journal of Pharmaceutical Research, 9(4), Suppl. 4, 325–326.
Acosta, E. (2009). Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Current Opinion in Colloid and Interface Science, 14(1), 3–15. https://doi.org/10.1016/j.cocis.2008.01.002
Aisen, P. S., & Davis, K. L. (1997). The search for disease-modifying treatment for Alzheimer’s Disease. Neurology, 48, 35–41. https://doi.org/10.1212/wnl.48.5_suppl_6.35s
Akhtar, S., & Benter, I. F. (2007). Nonviral delivery of synthetic siRNAs in vivo. Journal of Clinical Investigation, 117(12), 3623–3632. https://doi.org/10.1172/JCI33494
Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: Entering the mainstream. Science, 303(5665), 1818–1822. https://doi.org/10.1126/science.1095833
Amiri, H., Saeidi, K., Borhani, P., Manafirad, A., Ghavami, M., & Zerbi, V. (2013). Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents. ACS Chemical Neuroscience, 4(11), 1417–1429. https://doi.org/10.1021%2Fcn4001582
Ashrafi, H., Azadi, A., Mohammadi-Samani, S., & Hamidi, M. (2020). New candidate delivery system for Alzheimer’s disease: Deferoxamine nanogels. Biointerface Research in Applied Chemistry, 10(6), 7106–7119. https://doi.org/10.33263/BRIAC106.71067119
Ayaz, M., Ovais, M., Ahmad, I., Sadiq, A., Khalil, A. T., & Ullah, F. (2019). Biosynthesized metal nanoparticles as potential Alzheimer's disease therapeutics. In Metal Nanoparticles for Drug Delivery and Diagnostic Applications (pp. 31-42). Elsevier Inc. https://doi.org/10.1016/B978-0-12-816960-5.00003-3
Badry, A.E. & Mattar, M.A. (2017). Nanotechnology in Neurosurgical Practice. EC Neurology, 5(4), 149–171.
Bajaj, L., & Chopra, D. (2013). Preparation and Evaluation of rivastigmine Nanoparticles for Treatment of Dementia Associated with Alzheimer's disease. Retrieved 28 November 2023, from http://www.pharmatutor.org/articles/preparation-evaluation-rivastigmine-nanoparticles-treatment-dementia-associated-alzheimers-disease?page=0,0
Batrakova, E. V., Li, S., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2003). Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. Journal of Pharmacology and Experimental Therapeutics, 304(2), 845–854. https://doi.org/10.1124/jpet.102.043307
Bhavna, Md, S., Ali, M., Baboota, S., Sahni, J. K., Bhatnagar, A., & Ali, J. (2014). Preparation, characterisation, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Development and Industrial Pharmacy, 40(2), 278–287. https://doi.org/10.3109/03639045.2012.758130
Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kóňa, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S. M., Tvaroška, I., Couvreur, P., & Andrieux, K. (2012). Pegylated nanoparticles bind to and alter amyloid-beta peptide conformation: Toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano, 6(7), 5897–5908. https://doi.org/10.1021/nn300489k
Busquets, M. A., Sabaté, R., & Estelrich, J. (2014). Potential applications of magnetic particles to detect and treat Alzheimer's disease. Nanoscale Research Letters, 9(1), 1–10. https://doi.org/10.1186%2F1556-276X-9-538
Cai, W., & Chen, X. (2007). Nanoplatforms for targeted molecular imaging in living subjects. Small, 3(11), 1840–1854. https://doi.org/10.1002/smll.200700351
Cao, Y., & Zhang, R. (2022). The application of nanotechnology in treatment of Alzheimer's disease. Frontiers in Bioengineering and Biotechnology, 10, 1042986. https://doi.org/10.3389/fbioe.2022.1042986
Dobrovolskaia, M. A., & McNeil, S. E. (2007). Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), 469–478. https://doi.org/10.1038/nnano.2007.223
Dumurgier, J., & Tzourio, C. (2020). Epidemiology of neurological diseases in older adults. Revue Neurologique, 176(9), 642–648. https://doi:10.1016/j.neurol.2020.01.356
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., ... & Fischer, F. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(5), 459–480. https://doi.org/10.1016/S1474-4422(18)30499-X
Fradinger, E. A., & Bitan, G. (2005). En route to early diagnosis of Alzheimer's disease – Are we there yet? Trends in Biotechnology, 23(11), Suppl. 11, 531–533. https://doi.org/10.1016/j.tibtech.2005.09.002
Gok, M., Madrer, N., Zorbaz, T., Bennett, E. R., Greenberg, D., Bennett, D. A., & Soreq, H. (2022). Altered levels of variant cholinesterase transcripts contribute to the imbalanced cholinergic signaling in Alzheimer's and Parkinson's disease. Frontiers in Molecular Neuroscience, 15, 941467. https://doi.org/10.3389/fnmol.2022.941467
Gutiérrez, J. M., González, C., Maestro, A., Solè, I., Pey, C. M., & Nolla, J. (2008). Nanoemulsions: New applications and optimisation of their preparations. Current Opinion in Colloid and Interface Science, 13(4), 245–251. https://doi.org/10.1016/j.cocis.2008.01.005
Harper, J. D., Wong, S. S., Lieber, C. M., & Lansbury, P. T. (1999). Assembly of Aβ amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry, 38(28), Suppl. 28, 8972–8980. https://doi.org/10.1021/bi9904149
Hong-Qi, Y., Zhi-Kun, S., & Sheng-Di, C. (2012). Current advances in the treatment of Alzheimer's disease: Focused on considerations targeting Aβ and tau. Translational Neurodegeneration, 1(1), Suppl. 21, 21. https://doi.org/10.1186/2047-9158-1-21
Hostettmann, K., Borloz, A. U., Urbain, A., & Marston, A. (2006). Natural product inhibitors of acetylcholinesterase. Current Organic Chemistry, 10(8), 825–847. https://doi.org/10.2174/138527206776894410
Hunter, A. C., & Moghimi, S. M. (2003). Synthetic polymers in 21st century therapeutics: The way forward. Drug Discovery Today, 8(4), 154–156. https://doi.org/10.1016/s1359-6446(03)02605-9
Huwyler, J., Wu, D., & Pardridge, W. M. (1996). Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences of the United States of America, 93(24), 14164–14169. https://doi.org/10.1073/pnas.93.24.14164
Kabanov, A.V., Batrakova, E.V. & Alakhov, V.Y. (2003). An essential relationship between ATP depletion and chemosensitizing activity of pluronic block copolymers. Journal of Controlled Release, 91(1–2), 75–83. https://doi.org/10.1016/s0168-3659(03)00211-6
Kamei, N., Okada, N., Ikeda, T., Choi, H., Fujiwara, Y., Okumura, H., & Takeda-Morishita, M. (2018). Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction. Scientific Reports, 8(1), 17641. https://doi.org/10.1038/s41598-018-36210-9
Keating, C. D. (2005). Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proceedings of the National Academy of Sciences of the United States of America, 102(7), Suppl. 7, 2263–2264. https://doi.org/10.1073/pnas.0500024102
King, M., Su, W., Chang, A., Zuckerman, A., & Pasternak, G. W. (2001). Transport of opioids from the brain to the periphery by P-glycoprotein: Peripheral actions of central drugs. Nature Neuroscience, 4(3), 268–274. https://doi.org/10.1038/85115
Klajnert, B., Cortijo-Arellano, M., Cladera, J., & Bryszewska, M. (2006). Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochemical and Biophysical Research Communications, 345(1), Suppl. 1, 21–28. https://doi.org/10.1016/j.bbrc.2006.04.041
Kreuter, J. (2001). Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews, 47(1), 65–81. https://doi.org/10.1016/s0169-409x(00)00122-8
Kwon, G. S. (1998). Diblock copolymer nanoparticles for drug delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 15(5), 481–512. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v15.i5.20
Liu, X. G., Zhang, L., Lu, S., Liu, D. Q., Huang, Y. R., Zhu, J., Zhou, W. W., Yu, X. L., & Liu, R. T. (2020). Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer's Disease. Journal of Nanobiotechnology, 18(1), 160. https://doi.org/10.1186/s12951-020-00723-1
Lockman, P. R., Koziara, J., Roder, K. E., Paulson, J., Abbruscato, T. J., Mumper, R. J., & Allen, D. D. (2003). In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticles. Pharmaceutical Research, 20(5), 705-713. https://doi.org/10.1023/a:1023492015851
Mahmoudi, M., Quinlan-Pluck, F., Monopoli, M. P., Sheibani, S., Vali, H., Dawson, K. A., & Lynch, I. (2013). Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid beta protein fibrillation in solution. ACS Chemical Neuroscience, 4(3), 475–485. https://doi.org/10.1021/cn300196n
Mansoori, G. A. (2005). Principles of Nanotechnology: Molecular-Based Study of Condensed Matter in Small Systems. World Scientific Publishing, Co. https://doi.org/10.1142/5749
Mansoori, G. A., George, Th. F., Assoufid, L., & Zhang, G. (2007). Molecular building blocks for nanotechnology. Springer New York. https://doi.org/10.1007/978-0-387-39938-6
Mason, T. G., Graves, S. M., Wilking, J. N., & Lin, M. Y. (2006). Extreme emulsification: Formation and structure of nanoemulsions. Condensed Matter Physics, 9(1), Suppl. 1, 193–199. https://doi.org/10.5488/CMP.9.1.193
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006). Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. Journal of Neurochemistry, 97(6), Suppl. 6, 1700–1725. https://doi.org/10.1111/j.1471-4159.2006.03989.x
Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430(7000), 631–639. https://doi.org/10.1038/nature02621
Milane, L., & Amiji, M. (2021). Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 11, 1309–1315. https://doi.org/10.1007/s13346-021-00911-y
Mir Najib Ullah, S.N., Afzal, O., Altamimi, A.S.A., Ather, H., Sultana, S., Almalki, W.H., Bharti, P., Sahoo, A., Dwivedi, K., Khan, G., Sultana, S., Alzahrani, A., & Rahman, M. (2023). Nanomedicine in the Management of Alzheimer's Disease: State-of-the-Art. Biomedicines, 11(6), 1752. https://doi.org/10.3390/biomedicines11061752
Moghimi, S. M. (2011). Bionanotechnologies for treatment and diagnosis of Alzheimer's disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 7(5), 515–518. https://doi.org/10.1016/j.nano.2011.05.001
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: Current status and future prospects. The FASEB Journal, 19(3), 311–330. https://doi.org/10.1096/fj.04-2747rev
Mortimer, J. A., Borenstein, A. R., Gosche, K. M., & Snowdon, D. A. (2005). Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. Journal of Geriatric Psychiatry and Neurology, 18(4), Suppl. 4, 218–223. https://doi.org/10.1177/0891988705281869
Muller, H., Becker, R., Kruss, B., & Peters, K. (1999). Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. (US5858410A) U.S. Patent.
Nazem, A., & Mansoori, G. A. (2008). Nanotechnology solutions for Alzheimer's disease: Advances in research tools, diagnostic methods and therapeutic agents. Journal of Alzheimer's Disease, 13(2), 199–223. https://doi.org/10.3233/jad-2008-13210
Nazem, A., & Mansoori, G. A. (2011). Nanotechnology for Alzheimer's disease detection and treatment. Insciences Journal, 1(4), Suppl. 4, 169–193. https://doi.org/10.5640/insc.0104169
Nikakhtar, A., Nasehzadeh, A. & Mansoori, G.A. (2007). Formation and Stability Conditions of DNA-Dendrimer Nano-Clusters. Journal of Computational and Theoretical Nanoscience, 4, 521–528. https://doi.org/10.1166/jctn.2007.2337
Pagar, K., & Vavia, P. (2013). Rivastigmine-loaded L-Lactide-Depsipeptide polymeric nanoparticles: Decisive formulation variable optimisation. Scientia Pharmaceutica, 81(3), 865–885. https://doi.org/10.3797/scipharm.1211-20
Patel, D. A., Henry, J. E., & Good, T. A. (2007). Attenuation of β-amyloid induced toxicity by sialic acid-conjugated dendrimers: Role of sialic acid attachment. Brain Research, 1161, 95–105. https://doi.org/10.1016/j.brainres.2007.05.055
Patel, D., Henry, J., & Good, T. (2006). Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochimica et Biophysica Acta, 1760(12), Suppl. 12, 1802–1809. https://doi.org/10.1016/j.bbagen.2006.08.008
Prakash, J., Prakash, Prasad, V.V., Claret, A., Somasundaram, Rajan, S. (2022). Rivastigmine Loaded PEG-PLGA Nanoparticles for Enhanced Delivery to the Brain: In-Vitro and In-Vivo Studies for Alzheimer’s disease. Research Square, http://dx.doi.org/10.21203/rs.3.rs-1433109/v1
Quintana, C., Wu, T. D., Delatour, B., Dhenain, M., Guerquin-Kern, J. L., & Croisy, A. (2007). Morphological and chemical studies of pathological human and mice brain at the subcellular level: Correlation between light, electron, and NanoSIMS microscopies. Microscopy Research and Technique, 70(4), Suppl. 4, 281–295. https://doi.org/10.1002/jemt.20403
Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., Mallikarjuana, N. N., Manohar, S., Liang, H. F., Kulkarni, A. R., Sung, H. W., Sairam, M., & Aminabhavi, T. M. (2005). Targeted nanoparticles for drug delivery through the blood brain-barrier for Alzheimer's disease. Journal of Controlled Release, 108(2–3), 193–214. https://doi.org/10.1016/j.jconrel.2005.07.024
Selvin, P. R. (2000). The renaissance of fluorescence resonance energy transfer. Nature Structural Biology, 7(9), Suppl. 9, 730–734. https://doi.org/10.1038/78948
Sillerud, L. O., Solberg, N. O., Chamberlain, R., Orlando, R. A., Heidrich, J. E., Brown, D. C., Brady, C. I., Vander Jagt, T. A., Garwood, M., & Vander Jagt, D. L. (2013). SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain. Journal of Alzheimer's disease, 34(2), 349–365. https://doi.org/10.3233/JAD-121171
Silva, G. A. (2005). Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surgical Neurology, 63(4), Suppl. 4, 301–306. https://doi.org/10.1016/j.surneu.2004.06.008
Silva, G. A. (2010). Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. Annals of the New York Academy of Sciences, 1199, 221–230. https://doi.org/10.1111/j.1749-6632.2009.05361.x
Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004
Solans, C., Izquierdo, P., Nolla, J., Azemar, N., & Garcia-Celma, M. J. (2005). Nanoemulsions. Current Opinion in Colloid & Interface Science, 10(3-4), 102-110. https://doi.org/10.1016/j.cocis.2005.06.004
Song, Q., Huang, M., Yao, L., Wang, X., Gu, X., Chen, J., Chen, J., Huang, J., Hu, Q., Kang, T., Rong, Z., Qi, H., Zheng, G., Chen, H., & Gao, X. (2014). Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. ACS Nano, 8(3), Suppl. 3, 2345–2359. https://doi.org/10.1021/nn4058215
Sonneville-Aubrun, O., Simonnet, J. T., & L’Alloret, F. (2004). Nanoemulsions: A new vehicle for skincare products. Advances in Colloid and Interface Science, 108–109, 145–149. https://doi.org/10.1016/j.cis.2003.10.026.
Sood, S., Jain, K., & Gowthamarajan, K. (2013). Intranasal delivery of curcumin-donepezil nanoemulsion for brain targeting in Alzheimer's disease. Journal of the Neurological Sciences, 333, e316-e317. https://doi.org/10.1016/j.jns.2013.07.1182
Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2010). New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Advanced Drug Delivery Reviews, 62(4–5), 547–559. https://doi.org/10.1016/j.addr.2009.11.023
Viola, K. L., Sbarboro, J., Sureka, R., De, M., Bicca, M. A., Wang, J., Vasavada, S., Satpathy, S., Wu, S., Joshi, H., Velasco, P. T., MacRenaris, K., Waters, E. A., Lu, C., Phan, J., Lacor, P., Prasad, P., Dravid, V. P., & Klein, W. L. (2015). Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nature Nanotechnology, 10(1), 91–98. https://doi.org/10.1038/nnano.2014.254
Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M., Elliott, J. I., Li, Y., Scholtzova, H., Tang, C. Y., Aguinaldo, G., Pappolla, M., Duff, K., Wisniewski, T., & Turnbull, D. H. (2003). Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magnetic Resonance in Medicine, 50(2), 293–302. https://doi.org/10.1002/mrm.10529
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Ramasamy, M., & Suresh, B. (2010). Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology, and Medicine, 6(1), Suppl. 1, 144–152. https://doi.org/10.1016/j.nano.2009.04.001
Zhang, D., Tan, T., Gao, L., Zhao, W., & Wang, P. (2007). Preparation of azithromycin nanosuspensions by high pressure homogenisation and its physicochemical characteristics studies. Drug Development and Industrial Pharmacy, 33(5), Suppl. 5, 569–575. https://doi.org/10.1080/03639040600975147
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Dhivya P Sundaram, Swathy Govindaswamy, Sobiya Mathiazhagan, Jayalakshmi Venugopal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The observations and associated materials published or posted by NeurosciRN are licensed by the authors for use and distribution in accord with the Creative Commons Attribution license CC BY-NC 4.0 international, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
